immatics is developing cancer vaccines that help to activate the self defense mechanisms of the human body.
Our goal is to support patients and physicians with new options in the fight against various cancers.
Our means are synthetic peptides that specifically activate specialized white blood cells of the patient’s immune system against cancer cells.
Our first product for the treatment of kidney cancer, IMA901, has started a global Phase III clinical trial in 2011. Our second product for the treatment of colorectal cancer, IMA910, has completed a multi-center Phase II clinical trial. Our third product, IMA950 for the treatment of brain cancer, has recently entered clinical studies.
- -- 15 May 2013
immatics at EPIC Biotech Conference 2013 (June 6) in London, UK
- The 10th Anniversary EPIC Biotech Conference offers European and UK biotech companies, pharma, investors, CROs and delegates ... read more
- -- 15 May 2013
immatics at MASIR 2013 (May 29 – June 1) in Dubrovnik, Croatia
- MASIR conferences are focused on defining antigen-specific assays and the understanding of information which help to provide ... read more
- -- 14 May 2013
immatics at Sachs Cancer Bio Partnering (May 21 – 22) in Boston, US
- The Sachs Cancer Bio Partnering Forum enables leaders from cancer research institutes, patient advocacy groups, ... read more
Renal cell cancer phase III clinical trial
Drug: Peptide-based renal cell cancer vaccine IMA901...read more
Participating countries: France, Germany, Hungary, Italy, Poland, Russia, UK, USA, Netherlands, Norway
Glioblastoma phase I clinical trials
Drug: Peptide-based glioma vaccine IMA950...read more
Participating countries: UK & USA